DelveInsight’s “Microsatellite Stable Colorectal Cancer Market Insights, Epidemiology, and Market Forecast- 2032” report delivers an in-depth understanding of the Microsatellite Stable Colorectal Cancer, historical and forecasted epidemiology as well as the Microsatellite Stable Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock key insights into the Microsatellite Stable Colorectal Cancer Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Microsatellite Stable Colorectal Cancer Therapeutics Market Outlook

Key Takeaways from the Microsatellite Stable Colorectal Cancer Market Report

• In April 2025, Stingray Therapeutics announced a phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
• In April 2025, Redx Pharma Ltd announced a Phase II study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.
• In April 2025, Buzzard Pharmaceuticals conducted a study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
• Approximately 85 percent of instances of non-metastatic colorectal cancer (CRC) are associated with chromosomal instability and a proficient DNA Mismatch-Repair mechanism (pMMR); these cases are also known as CRC with microsatellite stability (MSS).
• In the United States, an estimated 104,610 new cases of colon cancer and 43,340 cases of rectal cancer will be diagnosed in 2020
• Men have a 30% greater CRC incidence rate than women.
• In their lifetime, around 4.4 percent of males (1 in 23) and 4.1 percent of women (1 in 25) will be diagnosed with CRC. Lifetime risk is equivalent in men and women, despite greater incidence rates in males because of women’s longer life expectancy.
• The relative survival rate for Colorectal cancer is 64 percent after 5 years of diagnosis and 58 percent after 10 years of diagnosis.
• The increase in Microsatellite Stable Colorectal Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Microsatellite Stable Colorectal Cancer Market is anticipated to witness growth at a considerable CAGR.
• The leading Microsatellite Stable Colorectal Cancer Companies such as Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec and others.
• Promising Microsatellite Stable Colorectal Cancer Pipeline Therapies such as Lenvatinib, Pembrolizumab (KEYTRUDA®), GI-101, Docetaxel, BMS-986340, Nivolumab, FOG-001, Balstilimab, Botensilimab and others.

Stay ahead in the competitive landscape of the Microsatellite Stable Colorectal Cancer Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Microsatellite Stable Colorectal Cancer Treatment Market Size

Microsatellite Stable Colorectal Cancer Epidemiology Segmentation in the 7MM

The epidemiology section of Microsatellite Stable Colorectal Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Microsatellite Stable Colorectal Cancer epidemiology trends @ Microsatellite Stable Colorectal Cancer Prevalence

Microsatellite Stable Colorectal Cancer Drugs Market

The Microsatellite Stable Colorectal Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Microsatellite Stable Colorectal Cancer signaling in Microsatellite Stable Colorectal Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.

Microsatellite Stable Colorectal Cancer Treatment Market Landscape

The Microsatellite Stable Colorectal Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Microsatellite Stable Colorectal Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Microsatellite Stable Colorectal Cancer treatment guidelines, visit @ Microsatellite Stable Colorectal Cancer Market Drivers and Barriers

Microsatellite Stable Colorectal Cancer Companies

Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec and others.

Microsatellite Stable Colorectal Cancer Market Outlook

The report’s outlook on the Microsatellite Stable Colorectal Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Microsatellite Stable Colorectal Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Microsatellite Stable Colorectal Cancer drug and late-stage pipeline therapy.

Microsatellite Stable Colorectal Cancer Drugs Uptake

The drug chapter of the Microsatellite Stable Colorectal Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Microsatellite Stable Colorectal Cancer.

Explore the dynamics of the Microsatellite Stable Colorectal Cancer Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Microsatellite Stable Colorectal Cancer Ongoing Clinical Trials Analysis

Scope of the Microsatellite Stable Colorectal Cancer Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Microsatellite Stable Colorectal Cancer Companies- Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec, and others.
• Microsatellite Stable Colorectal Cancer Pipeline Therapies- Lenvatinib, Pembrolizumab (KEYTRUDA®), GI-101, Docetaxel, BMS-986340, Nivolumab, FOG-001, Balstilimab, Botensilimab and others.
• Microsatellite Stable Colorectal Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Microsatellite Stable Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Microsatellite Stable Colorectal Cancer Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Executive Summary of Microsatellite Stable Colorectal Cancer

3. Competitive Intelligence Analysis for Microsatellite Stable Colorectal Cancer

4. Microsatellite Stable Colorectal Cancer: Market Overview at a Glance

5. Microsatellite Stable Colorectal Cancer: Disease Background and Overview

6. Microsatellite Stable Colorectal Cancer Patient Journey

7. Microsatellite Stable Colorectal Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Microsatellite Stable Colorectal Cancer Unmet Needs

10. Key Endpoints of Microsatellite Stable Colorectal Cancer Treatment

11. Microsatellite Stable Colorectal Cancer Marketed Products

12. Microsatellite Stable Colorectal Cancer Emerging Therapies

13. Microsatellite Stable Colorectal Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Microsatellite Stable Colorectal Cancer Market Outlook

16. Access and Reimbursement Overview of Microsatellite Stable Colorectal Cancer

17. Microsatellite Stable Colorectal Cancer KOL Views

18. Microsatellite Stable Colorectal Cancer Market Drivers

19. Microsatellite Stable Colorectal Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market